Abstract
Incidental findings on newborn screening (NBS) are results that are not the target of screening within a given NBS program, but rather are found as a result of the screening and resulting diagnostic workup for that target. These findings may not have an immediate clinical impact on the newborn, but are sometimes an additional benefit of NBS programs and may be considered secondary targets of NBS programs. This work describes four case reports that had incidental findings on the NBS, which eventually led to the diagnosis of another metabolic disease instead of the one that was initially suspected. The first case was a new defect in the cationic amino acid transporter-2 (CAT-2), which was oriented as an arginase-1 deficiency in the newborn. The second case was a maternal glutaric aciduria type 1 (GA-1) that mimicked a carnitine transporter deficiency in the newborn. The third report was a case of lysinuric protein intolerance (LPI), which appeared as high levels of citrulline on the NBS. The fourth case was a mother with homocystinuria that was diagnosed during the biochemical study of vitamin B12 status. All cases provide new or interesting data that will help guide differential diagnosis in the future.
Highlights
The most important technological advance applied to newborn screening (NBS) in recent decades has been the introduction of tandem mass spectrometry for the early detection of inherited metabolic diseases [1]
Expanded NBS for inborn errors of metabolism is a promising field of targeted metabolomics
The different diagnostic tests performed on the patient ruled out arginase-1 deficiency. This case illustrates the importance of continuing to investigate an unexplained finding in order to contribute to advancing the knowledge of hereditary metabolic diseases. It highlights the role of generation sequencing (NGS) techniques that allow for the identification of the molecular defect and the possibility, as in this case, of discovering a new disorder through an incidental finding on an expanded NBS
Summary
The most important technological advance applied to newborn screening (NBS) in recent decades has been the introduction of tandem mass spectrometry for the early detection of inherited metabolic diseases [1]. This technology allows for the simultaneous measurement of amino acids and. Genes 2020, 11, 1018 acylcarnitines in order to identify newborns at risk of suffering from certain aminoacidopathies, some organic acidurias, and fatty acid oxidation disorders This is known as “expanded” NBS and it is estimated that up to 70 metabolic diseases and other clinical conditions can potentially be detected [2].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.